ABSTRACT
CASE REPORT: The effect of a somatostatin analogue in a patient with Graves' ophthalmopathy is presented, including data on the dose requirements and the results of therapy. DISCUSSION: There are few effective options for the management of Graves' ophthalmopathy, a cell-mediated immune co-morbidity of thyroid disease. Somatostatin analogues inhibit lymphocyte proliferation and activation, and accumulate in the orbital tissue during the active ophthalmopathy. Because of this, such therapy is able to inactivate the ophthalmopathy without complications occurring.
Subject(s)
Graves Ophthalmopathy/drug therapy , Peptides, Cyclic/therapeutic use , Somatostatin/analogs & derivatives , Adult , Humans , Male , Somatostatin/therapeutic useABSTRACT
No disponible
Subject(s)
Humans , Recurrence , Antithyroid Agents , Carbimazole , Graves DiseaseSubject(s)
Antithyroid Agents/therapeutic use , Graves Disease/drug therapy , Adult , Aged , Female , Humans , Male , Middle Aged , Prognosis , Recurrence , Retrospective StudiesABSTRACT
No disponible
Subject(s)
Middle Aged , Adult , Aged , Male , Female , Humans , Antithyroid Agents , Recurrence , Prognosis , Retrospective Studies , Graves DiseaseABSTRACT
No disponible
No disponible
Subject(s)
Adult , Male , Humans , Thyrotropin , Octreotide , Antineoplastic Agents, Hormonal , Adenoma , Pituitary NeoplasmsABSTRACT
Leukemia is an uncommon complication of exposure to radioiodine (131I), used in treatment of thyroid cancer, because low doses are now used. We report two cases of acute myelogenous leukemia developed after the treatment of a thyroid carcinoma with a small dose of 131I.
Subject(s)
Carcinoma, Papillary/radiotherapy , Iodine Radioisotopes/adverse effects , Leukemia, Myeloid, Acute/etiology , Leukemia, Promyelocytic, Acute/etiology , Leukemia, Radiation-Induced/etiology , Neoplasms, Second Primary/etiology , Thyroid Neoplasms/radiotherapy , Adult , Female , Humans , Iodine Radioisotopes/administration & dosageSubject(s)
Anemia, Refractory/complications , Diabetes Insipidus/complications , Aged , Humans , MaleABSTRACT
The surgical treatment of hypophyseal tumors has improved from external approach (transcranial-subtemporal) to the trans-septo-transphenoidal approach. Since the last thirty years this way to access has been increasingly used, because it provides an excellent exposure, little bleeding, is rapidly and easily performed with less morbi-morality and has smoother postoperative period. A retrospective study of 16 patients whose hypophyseal tumors were treated surgically using the trans-septo-sphenoidal transnasal (maxillary-premaxillary) approach is presented. All these patients were seen in the E.N.T. Department of Alicante's General University Hospital, between January 1990 and June 1993. The trans-septo-sphenoidal transnasal via avoids some of the problems of the sublabial trans-sphenoidal procedure; namely longer operating time, oral contamination of the surgical field, subsequence difficulties due to the lack of sensibility and discomfort of the upper jax area and postoperative alterations in the projection of the septal-columelar tip.
